Table of Contents
ISRN Rheumatology
Volume 2011, Article ID 580704, 6 pages
http://dx.doi.org/10.5402/2011/580704
Research Article

Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP Improves

1Department of Medicine, University of Western Ontario, London, ON, Canada N6A 5C1
2Screening Laboratory for Immune Disorders, Lawson Health Research Institute, London, ON, Canada N6A 4V2
3Department of Microbiology & Immunology, University of Western Ontario, London, ON, Canada N6A 5C1
4Rheumatology, St. Joseph's Health Care London, London, ON, Canada N6A 4V2
5Department of Mathematics and Statistics, McMaster University, Hamilton, ON, Canada L8S 4K1

Received 6 May 2011; Accepted 27 June 2011

Academic Editors: M. G. Danieli, B. A. Eberhard, C. G. Mackworth-Young, and C.-H. Suh

Copyright © 2011 Déanne Malenfant et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. G. Suter, J. M. Murabito, D. T. Felson, and L. Fraenkel, “The incidence and natural history of Raynaud's phenomenon in the community,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1259–1263, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Bakst, J. F. Merola, A. G. Franks, and M. Sanchez, “Raynaud's phenomenon: pathogenesis and management,” Journal of the American Academy of Dermatology, vol. 59, no. 4, pp. 633–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. N. Lambova and U. Müller-Ladner, “New lines in therapy of Raynaud's phenomenon,” Rheumatology International, vol. 29, no. 4, pp. 355–363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Kahaleh, O. Meyer, and R. Scorza, “Assessment of vascular involvement,” Clinical and Experimental Rheumatology, vol. 21, no. 3, pp. S9–S14, 2003. View at Google Scholar · View at Scopus
  5. S. Rajagopalan, D. Pfenninger, C. Kehrer et al., “Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon,” Arthritis and Rheumatism, vol. 48, no. 7, pp. 1992–2000, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J. E. Pope, “The diagnosis and treatment of Raynaud's phenomenon: a practical approach,” Drugs, vol. 67, no. 4, pp. 517–525, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. E. Thompson and J. E. Pope, “Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis,” Rheumatology, vol. 44, no. 2, pp. 145–150, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. E. Thompson, B. Shea, V. Welch, D. Fenlon, and J. E. Pope, “Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis,” Arthritis and Rheumatism, vol. 44, no. 8, pp. 1841–1847, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Coleiro, S. E. Marshall, C. P. Denton et al., “Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine,” Rheumatology, vol. 40, no. 9, pp. 1038–1043, 2001. View at Google Scholar · View at Scopus
  10. J. Pope, D. Fenlon, A. Thompson et al., “Systemic Sclerosis (SS): ketanserin versus placebo for the treatment of Raynaud's phenomenon in progressive SS,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD000954, 2000. View at Google Scholar
  11. A. L. Herrick, “Pathogenesis of Raynaud's phenomenon,” Rheumatology, vol. 44, no. 5, pp. 587–596, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Clement, C. R. Covertson, M. J. Johnson, and K. Dearing, “St. John's Wort and the treatment of mild to moderate depression: a systematic review,” Holistic Nursing Practice, vol. 20, no. 4, pp. 197–203, 2006. View at Google Scholar · View at Scopus
  13. Y. Lecrubier, G. Clerc, R. Didi, and M. Kieser, “Efficacy of St. John's Wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial,” American Journal of Psychiatry, vol. 159, no. 8, pp. 1361–1366, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Schrader, “Equivalence of St John's Wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression,” International Clinical Psychopharmacology, vol. 15, no. 2, pp. 61–68, 2000. View at Google Scholar · View at Scopus
  15. V. Schulz, “Safety of St. John's Wort extract compared to synthetic antidepressants,” Phytomedicine, vol. 13, no. 3, pp. 199–204, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Kasper, I. G. Anghelescu, A. Szegedi, A. Dienel, and M. Kieser, “Superior efficacy of St John's Wort extract WS®5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298],” BioMed Central Medicine, vol. 4, p. 14, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Mannel, U. Kuhn, U. Schmidt, M. Ploch, and H. Murck, “St. John's Wort extract LI160 for the treatment of depression with atypical features—a double-blind, randomized, and placebo-controlled trial,” Journal of Psychiatric Research, vol. 44, no. 12, pp. 760–767, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. P. A. Merkel, K. Herlyn, R. W. Martin et al., “Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon,” Arthritis and Rheumatism, vol. 46, no. 9, pp. 2410–2420, 2002. View at Publisher · View at Google Scholar · View at Scopus